CY1111958T1 - Θεραπευτικη χρηση αντισωματων anti-csi - Google Patents

Θεραπευτικη χρηση αντισωματων anti-csi

Info

Publication number
CY1111958T1
CY1111958T1 CY20111100687T CY111100687T CY1111958T1 CY 1111958 T1 CY1111958 T1 CY 1111958T1 CY 20111100687 T CY20111100687 T CY 20111100687T CY 111100687 T CY111100687 T CY 111100687T CY 1111958 T1 CY1111958 T1 CY 1111958T1
Authority
CY
Cyprus
Prior art keywords
antagonists
bind
subject
antibodies treatment
present
Prior art date
Application number
CY20111100687T
Other languages
English (en)
Inventor
Marna Williams
Yun J Tso
Nicolas F Landolfi
David B Powers
Gao Liu
Original Assignee
Abbott Biotherapeutics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotherapeutics Corp. filed Critical Abbott Biotherapeutics Corp.
Publication of CY1111958T1 publication Critical patent/CY1111958T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Luminescent Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ανταγωνιστές του CS1 που δεσμεύονται με CS1 και εξουδετερώνουν τουλάχιστον μία βιολογική δραστικότητα του. Η εφεύρεση περιλαμβάνει επίσης φαρμακευτική σύνθεση που περιλαμβάνει τέτοια αντισώματα ή θραύσματα αυτών που δεσμεύονται με το αντιγόνο. Η παρούσα εφεύρεση παρέχει επίσης μέθοδο πρόληψης ή θεραπευτικής αγωγής καταστάσεων ασθενειών που περιλαμβάνουν αυτοάνοσες διαταραχές και καρκίνο, σε υποκείμενο που χρήζει αγωγής, η οποία μέθοδος περιλαμβάνει χορήγηση αποτελεσματικής ποσότητας τέτοιων ανταγωνιστών σε αυτό το υποκείμενο.
CY20111100687T 2003-05-08 2011-07-14 Θεραπευτικη χρηση αντισωματων anti-csi CY1111958T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US55762004P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
EP04760993A EP1624892B1 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
CY1111958T1 true CY1111958T1 (el) 2015-11-04

Family

ID=33459144

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20111100687T CY1111958T1 (el) 2003-05-08 2011-07-14 Θεραπευτικη χρηση αντισωματων anti-csi
CY20141100872T CY1115671T1 (el) 2003-05-08 2014-10-23 Θεραπευτικη χρηση αντισωματων anti-cs1
CY2016035C CY2016035I1 (el) 2003-05-08 2016-10-26 Θεραπευτικη χρηση αντισωματων anti-cs1
CY20171100980T CY1119353T1 (el) 2003-05-08 2017-09-15 Θεραπευτικη χρηση αντισωματων anti-cs1

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY20141100872T CY1115671T1 (el) 2003-05-08 2014-10-23 Θεραπευτικη χρηση αντισωματων anti-cs1
CY2016035C CY2016035I1 (el) 2003-05-08 2016-10-26 Θεραπευτικη χρηση αντισωματων anti-cs1
CY20171100980T CY1119353T1 (el) 2003-05-08 2017-09-15 Θεραπευτικη χρηση αντισωματων anti-cs1

Country Status (25)

Country Link
US (8) US20050025763A1 (el)
EP (4) EP2371391B1 (el)
JP (4) JP4887152B2 (el)
KR (1) KR101268707B1 (el)
CN (1) CN1805755B (el)
AT (1) ATE506076T1 (el)
AU (2) AU2004238363B2 (el)
BE (1) BE2016C056I2 (el)
BR (1) BRPI0410129B8 (el)
CA (1) CA2523001C (el)
CY (4) CY1111958T1 (el)
DE (1) DE602004032328D1 (el)
DK (3) DK2853272T3 (el)
ES (2) ES2643289T3 (el)
FR (1) FR16C1012I2 (el)
HK (3) HK1089374A1 (el)
HU (2) HUE034908T2 (el)
LT (1) LT2853272T (el)
LU (1) LU93274I2 (el)
MX (1) MXPA05012011A (el)
NL (1) NL300838I2 (el)
PL (3) PL1624892T3 (el)
PT (3) PT2371391E (el)
SI (3) SI2371391T1 (el)
WO (1) WO2004100898A2 (el)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
DK2068874T3 (da) * 2006-08-07 2015-04-27 Abbvie Biotherapeutics Inc Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
WO2008019379A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
EP2068930B1 (en) * 2006-08-07 2012-09-19 Abbott Biotherapeutics Corp. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
KR20110096536A (ko) * 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
CA2749093C (en) * 2009-01-08 2019-03-26 Bio-Rad Laboratories, Inc. Exonuclease deficient hybrid polymerase and uses thereof in amplification reactions
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
AU2011209713B2 (en) * 2010-01-28 2014-04-03 Glaxo Group Limited CD127 binding proteins
UA123257C2 (uk) * 2010-02-24 2021-03-10 Іммуноджен, Інк. Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1
PT2694106T (pt) 2011-04-01 2018-03-05 Immunogen Inc Métodos para aumentar eficácia de terapia de cancro de folr1
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
CN105377892A (zh) * 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
ES2699599T3 (es) * 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
CN105377897A (zh) * 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
EP3024482A4 (en) * 2013-07-24 2017-03-15 The General Hospital Corporation Methods for diagnosing and treating immune disease
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US9482289B2 (en) 2013-10-14 2016-11-01 Club Car, Llc Self-preloading shift lever
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
CA2947646A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
ES2779412T3 (es) * 2014-06-17 2020-08-17 Medimmune Ltd Anticuerpos Alfa-V Beta-8 mejorados
EP3169773B1 (en) 2014-07-15 2023-07-12 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
ES2832711T3 (es) 2014-10-31 2021-06-11 Abbvie Biotherapeutics Inc Anticuerpos anti-CS1 y conjugados anticuerpo fármaco
CA2969665A1 (en) 2014-12-04 2016-06-09 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
DE102015102183B4 (de) * 2015-02-16 2018-03-01 Robert Bosch Automotive Steering Gmbh Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug
KR102606190B1 (ko) 2015-02-20 2023-11-23 오하이오 스테이트 이노베이션 파운데이션 Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
WO2016168766A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
EA035888B1 (ru) 2015-06-29 2020-08-27 Бристол-Майерс Сквибб Компани Режимы дозирования иммунотерапевтических средств и их комбинаций
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CA3055965A1 (en) 2017-03-13 2018-09-20 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
WO2018182529A1 (en) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anti oligosaccharide antibody
BR112019027133B8 (pt) 2017-06-20 2022-08-23 Inst Curie Uso de uma célula imune modificada deficiente para suv39h1
CN111133002B (zh) * 2017-08-07 2024-05-24 恩比伊治疗股份公司 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
AU2018360801A1 (en) 2017-11-01 2020-05-14 Celgene Corporation Process for producing a T cell composition
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200099132A (ko) 2017-11-01 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 조작된 세포의 치료적 조성물을 생성하기 위한 프로세스
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
US20210128616A1 (en) 2017-12-08 2021-05-06 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
BR112020011215A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc processo para a produção de uma composição de células t modificadas
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
MA52235A (fr) * 2018-03-05 2021-02-17 Janssen Pharmaceutica Nv Anticorps anti-phf-tau et leurs utilisations
WO2020002592A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Traf2 inhibitors for use in the treatment of a cancer
JP7538109B2 (ja) 2018-08-09 2024-08-21 ジュノー セラピューティクス インコーポレイテッド 組み込まれた核酸を評価するための方法
CN109406798A (zh) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 肌酐酶法检测试剂盒
JP2022506598A (ja) 2018-11-01 2022-01-17 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods for activating inactive immune cells and cancer treatment
KR20220016474A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
CN114222815A (zh) 2019-07-23 2022-03-22 记忆疗法公司 Suv39h1缺陷的免疫细胞
JP2022553821A (ja) 2019-11-05 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー Ｍ－タンパク質アッセイおよびその使用
BR112022015523A2 (pt) * 2020-02-05 2022-09-27 Navaux Inc Anticorpos anti-hepsina e seus usos
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
AU2021316727A1 (en) 2020-07-30 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SOCS1
CN116802203A (zh) 2020-11-04 2023-09-22 朱诺治疗学股份有限公司 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
EP4337763A1 (en) 2021-05-10 2024-03-20 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
EP4346912A1 (en) 2021-05-25 2024-04-10 Institut Curie Myeloid cells overexpressing bcl2
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
TW202342520A (zh) 2022-02-18 2023-11-01 美商樂天醫藥生技股份有限公司 抗計畫性死亡配體１（ｐｄ—ｌ１）抗體分子、編碼多核苷酸及使用方法
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO2000073454A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002540763A (ja) 1999-02-10 2002-12-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３３個のヒト分泌タンパク質
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3750000A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
JP3951035B2 (ja) 1999-09-01 2007-08-01 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ20023203A3 (cs) * 2000-03-24 2003-08-13 Micromet Ag Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
AU2001266604A1 (en) 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
JP2005503109A (ja) * 2001-01-29 2005-02-03 アイデック ファーマスーティカルズ コーポレイション 修飾抗体と使用方法
EP1390390A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR20110096536A (ko) 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
KR102028770B1 (ko) 2011-09-15 2019-10-04 컨버전트 인포메이션 테크놀로지스 게엠베하 로봇 프로그램의 자동 생성을 위한 시스템 및 방법
WO2013123099A1 (en) 2012-02-13 2013-08-22 Radius Engineering Inc. Reusable cartridge for injection molding

Also Published As

Publication number Publication date
DK1624892T3 (da) 2011-08-08
PL2371391T3 (pl) 2015-01-30
CA2523001C (en) 2013-12-31
US20090238835A1 (en) 2009-09-24
HUS1600042I1 (hu) 2016-11-28
JP5976288B2 (ja) 2016-08-23
BRPI0410129B8 (pt) 2021-05-25
BRPI0410129A (pt) 2006-05-16
JP2012121878A (ja) 2012-06-28
WO2004100898A2 (en) 2004-11-25
EP2853272A1 (en) 2015-04-01
JP2017019795A (ja) 2017-01-26
BRPI0410129B1 (pt) 2020-02-11
PT1624892E (pt) 2011-07-12
HK1208815A1 (en) 2016-03-18
BE2016C056I2 (el) 2023-08-09
AU2010214661A1 (en) 2010-09-16
CA2523001A1 (en) 2004-11-25
JP2014139187A (ja) 2014-07-31
CN1805755A (zh) 2006-07-19
US20140065063A1 (en) 2014-03-06
US8133981B2 (en) 2012-03-13
CY1119353T1 (el) 2018-02-14
CY2016035I2 (el) 2017-09-13
MXPA05012011A (es) 2006-02-03
JP4887152B2 (ja) 2012-02-29
DK2371391T3 (da) 2014-11-03
US8008450B2 (en) 2011-08-30
FR16C1012I2 (fr) 2019-01-11
JP2007503465A (ja) 2007-02-22
ES2516840T3 (es) 2014-10-31
AU2010214661B2 (en) 2012-05-17
DE602004032328D1 (de) 2011-06-01
LT2853272T (lt) 2017-10-10
US20200031929A1 (en) 2020-01-30
EP2371391B1 (en) 2014-07-23
CN1805755B (zh) 2011-06-01
EP3275463A1 (en) 2018-01-31
ATE506076T1 (de) 2011-05-15
HUE034908T2 (hu) 2018-03-28
LU93274I2 (fr) 2016-12-27
US9175081B2 (en) 2015-11-03
ES2643289T3 (es) 2017-11-22
EP1624892A4 (en) 2007-08-08
SI1624892T1 (sl) 2011-08-31
EP2853272B1 (en) 2017-08-02
PL2853272T3 (pl) 2018-01-31
HK1089374A1 (en) 2006-12-01
EP1624892A2 (en) 2006-02-15
SI2853272T1 (sl) 2017-10-30
HK1163497A1 (en) 2012-09-14
CY2016035I1 (el) 2017-09-13
DK2853272T3 (da) 2017-11-06
AU2004238363B2 (en) 2010-05-27
EP1624892B1 (en) 2011-04-20
US20160002335A1 (en) 2016-01-07
PL1624892T3 (pl) 2011-09-30
US20090238827A1 (en) 2009-09-24
US8445646B2 (en) 2013-05-21
EP2371391A1 (en) 2011-10-05
KR20060018837A (ko) 2006-03-02
KR101268707B1 (ko) 2013-05-29
NL300838I2 (el) 2017-01-03
AU2004238363A1 (en) 2004-11-25
US20050025763A1 (en) 2005-02-03
SI2371391T1 (sl) 2014-12-31
FR16C1012I1 (el) 2016-09-12
PT2371391E (pt) 2014-10-30
CY1115671T1 (el) 2017-01-25
JP6042834B2 (ja) 2016-12-14
US10442859B2 (en) 2019-10-15
WO2004100898A3 (en) 2005-08-18
PT2853272T (pt) 2017-08-30
US20100168397A1 (en) 2010-07-01
US20120064083A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
IL178121A (en) Anti-cs-1 antibodies for the treatment of multiple myeloma
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
CY1107453T1 (el) Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
TH1601004178A (th) ฮิวเมนแอนติบอดีต่อ pd-1
CY1114921T1 (el) Αντισωματα που δεσμευονται ανοσοειδικα στους trail υποδοχεις
CY1117037T1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματικης ασθενεια